Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)
Source: SeekingAlpha
2025-12-02 07:12:48 ET
Overview
My first look at Janux Therapeutics ( JANX ) was in April 2024. Then, the company had just reported Phase 1a data for its PSMA-tumor activated T cell engager, JANX007, in metastatic castration-resistant prostate cancer, or mCRPC....
Read the full article on Seeking Alpha
For further details see:
Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade)
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
